Handbook Handb HANDBOOK

Handbook Handbook

ViršelisLSB Logo su data ir tekstasConference Programme & Exhibition book

H A N D B O O K

It is indeed my great pleasure to welcome you to the Life Sciences Baltics forum. Thank you to each and every one of you for being here with us the whole week, September 20-24.

At Enterprise Lithuania we are pursuing our work and our efforts to support the greater role for Lithuania’s life sciences in Europe and the world. Seeing the robust and growing community of life sciences in Lithuania, we took a bold action to start Life Sciences Baltics back in 2012. Now, it is the biggest event in Eastern and Central Europe, dedicated exceptionally for life sciences experts, businesses, startups from all around the world.

This year, we had to move the forum online and were initially a bit unsure of how it would go. But the strong interest from the global biotech community has proven that the Baltics are very much on the radar currently.

With a year-on-year exports increase of 22%, Lithuania has the fastest-growing life sciences sector in the EU. Biotech subsector remained resilient amid COVID-19 pandemią. What is more, during the last year only our life sciences export grew by astonishing 62 per cent in total and the same pace of growth is witnessed this year as well. Lithuania has an ambitious goal to increase this industry share from GDP up to the 5% by the end of decade.

Almost 1000 participants gathered online for the fifth Life Sciences Baltics. We are joined by more

Dear Life Sciences Community,

than 60 guest speakers and lecturers, 30 life sciences startups from all around the world, more than 70 companies in the virtual exhibition and around 50 researchers presenting their discoveries and insights at the poster session. Many business, government and academic representatives from the United States, Germany, the United Kingdom, Japan, Israel, Austria, Belgium, Denmark, Latvia, Estonia and many other countries are here with us today.

The programe of this international conference will focus on topics where the Baltics excel - digital health, gene editing, MedTech, early drug discovery, imaging, personalized medicine and the microbiome. Furthermore, we designed the programme that is both responsive to national as well as international concerns. I believe the upcoming discussion about the countries case studies on managing COVID-19 as well as the COVID-19 session will be the most anticipated parts of the event.

Yet, first and foremost, this forum is about making connections. Life Sciences Baltics not only builds new business collaboration partnerships which eventually lead to success stories but also provides a unique opportunity for the Baltics to be considered as the desirable partner in the field of life sciences. I wish that this week all participants are taking the opportunity to build bridges for new projects and ideas.

I sincerely hope you will enjoy Life Sciences Baltics Forum’s debates, discussions and insights.

DAINA KLEPONĖGeneral Manager of Enterprise Lithuania

DAY 1 (September 22)

10:00-10:15 Opening

10:15-11:00

Dr. Richard Henderson CryoEM in Structural Biology2017 Nobel Prize in Chemistry,

MRC Laboratory of Molecular Biology, United Kingdom

11:00-11:30Discussion with Nobel laureate Dr. Richard Henderson

Moderator: Raminta TomkutėBiotherapeutics formulation scientist and alumna of University of Cambridge, United Kingdom

11:25-11:40 Coffee break Powered by AbbVie and Innovative Pharmaceutical Industry Association

Session 1:The Perspectives of Personalized Medicine in Practice Powered by

Medirex Group, Roche and Novartis (11:40-13:30)

Session 4:Emerging Technologies for Medicine

(11:40-13:30)

Bogi Eliasen„The Genomic Revolution of Understanding and Treating Disease Towards

Precision Medicine“Director of Health,

Copenhagen Institute for Futures Studies, DenmarkPowered by Roche

Prof. Ivo Fridolin, PhD“Spectrophotometric Eyes for Artificial Kidney Performance Monitoring”

Professor, Tallinn University of Technology, Estonia

Prof. Andres Metspalu, MD, PhD“Estonian Biobank - a Step Towards Personalized Medicine”

Professor, University of Tartu, Estonia

Arnas Karužas, MD„Artificial Intelligence in Heart Ultrasound“

CEO, LIGENCE, Lithuania

Tomas Szemes, RNDr, PhD“Genome Technologies and Advanced Bioinformatics are Turning the Vision

of Personalized Precision Medicine into Reality”Chief Scientific Officer, Geneton,

Genomics Core Lab Manager, Comenius University Science Park, SlovakiaPowered by Medirex Group

Prof. Dr. Luca Battistelli, MSc“CAR-T Cell Therapy: A New Era in Cancer Immunotherapy”

Technology Transfer and Grant Office Manager,Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” IRCCS-IRST, Italy

Discussion: “Precision Medicine: Are We Ready for the Grand Transformation in Medical

Practice?”Moderator: Prof. Sonata Jarmalaitė

Participants: Bogi Eliasen

Prof. Andres Metspalu, MD, PhD Tomas Szemes, RNDr, PhD

Discussion: “Speeding Up Implementation: From Idea to Implementation Through

Regulation”Moderator: Martynas Osauskas

Participants: Prof. Ivo Fridolin, PhD

Arnas Karužas, MDProf. Dr. Luca Battistelli, MSc

Stefan Bolleininger

13:30-13:45 Coffee Break Powered by AbbVie and Innovative Pharmaceutical Industry Association

Session 2:Digital Health Powered by Teva Baltics

(13:45-15:40)

Session: 5 Microscopic Image Analysis in the Age of AI.

Powered by ZEISS & APEER(13:45-16:40)

Prof. Mark van Gils, PhD“Can We Achieve Smart Health with Smart Technologies?”

Professor in Digital Healthcare, Tampere University, Finland

Dr. Bernhard Schwarz, Head of FoB Aftersales & FoB Software, ZEISS Research Microscopy Solutions, Germany

Dr. Urtė Neniškytė, PhD“Machine Learning Approach for Morphological Analysis of Dendritic

Spines”Neurobiology and Biophysics, Vilnius University Life Sciences Center,

Lithuania

Jan Kimpen, MD“Enabling the Digital Transformation in Healthcare”

Chief Medical Officer, Philips, Netherlands

“Molecular Mechanisms of Anticancer Drug Resistance”Mindaugas Valius, PhD

Head of Proteomics Center, Institute of Biochemistry, Vilnius University Life Sciences Center, Lithuania

Nadežda Dreižė, PhDProtemics Center, Vilnius University Life Sciences Center, Lithuania

Harsh Dharwad, “Predicting Clinical Events – Future of Digital Health”

President & CEO, Nihon Kohden Digital Health Solutions, USA

Prof. Arvydas Laurinavičius, MD, PhD “Digital Intelligence for Tissue Pathology Testing”

Director of the National Pathology Centre, Vilnius University, Faculty of Medicine, Vilnius University Hospital Santaros klinikos, Lithuania

Discussion:“Is Explainable AI Needed in Digital Health?”

Moderator: Prof. Habil Dr. Arūnas LukoševičiusParticipants: Harsh Dharwad, Jan Kimpen, MD, Prof. Mark van Gils,

PhD, Dr. Alexander Nuyken

Karolis Leonavičius, PhD“AI in High-Speed Microscopic Particle Analysis”

CTO, Droplet Genomics, Lithuania

Session 3:Microbiome and Health: Current Applications and Future

Challenges (15:40-17:30)

Live Q&A SessionProf. Georgina Hold,

“What is a Healthy Microbiome?”Professor, University of New South Wales, Australia

Prof. Jasmohan S. Bajaj,“The Gut and Brain Axis: Is Microbiome a Key Player?”

Professor, Virginia Commonwealth University, USA

Prof. Juozas Kupčinskas, MD, PhD“Current Challenges and Future of Microbiome Manipulation in

Humans”Head of Gastroenterology Department, The Hospital of Lithuanian

University of Health Sciences Kauno klinikos, Lithuania

Discussion:“How to Narrow the Gap Between Fundamental Microbiome Research

and Clinical Practice?”Moderator: Prof. Juozas Kupčinskas, MD, PhD

Participants: Prof. Jasmohan S. Bajaj

Prof. Georgina HoldProf. Dr. Alexander Link

16:40-17:30

Discussion on Lithuanian life sciences ecosystem

Moderator: TBC

Participants: TBC

10:00-10:20 Opening

10:20-11:35

Discussion: COVID-19 Different Country Case Studies

Participants:1. Prof. Ran Balicer, MD, PhD, MPH, Chairperson at National Covid-19 National Experts Advisory Team, Israel

2. Prof. Michael Baker, Member of the Ministry of Health’s Covid-19 Technical Advisory Group, leading architect and advocate for the Covid-19 elimination strategy in New Zealand

3. Prof. Mindaugas Stankūnas, MPH, PhD, Member of National Covid-19 National Experts Advisory Team, Lithuanian University of Health Sciences, LithuaniaModerator: Prof. Ligita Jančorienė, Vilnius University, Medical Faculty, Institute of Clinical Medicine, Head of Centre of Infectious Diseases, Vilnius University

Hospital Santaros klinikos, Lithuania

11:35-12:25

Katherine High, MD „Turning Genes into Medicines: Gene Therapy for Genetic Disease“

President and Head of R&D, CO-Founder Spark Therapeutics, USA

12:25-12:35 Coffee Break Powered by AbbVie and Innovative Pharmaceutical Industry Association

DAY 2 (September 23)

Session 6:Gene Editing & Applications Powered by Thermo Fisher Scientific

(12:35-14:50)

Session 7: COVID-19 Session Powered by Clarivate Analytics(12:35-14:15)

Prof. Dr. Virginijus Šikšnys“CRISPR-Cas tools: where we are and what is next”

Chief Scientist and Head of Department of Protein, Vilnius University Life Sciences Centre, Lithuania

Rein Sikut, PhD “Development of New Vaccines in Pandemic Situation: Too Fast or

Too Slow?”Medical Manager Vaccines & Immunology, Johnson & Johnson,

Estonia

Dr. Karl von Laer“New Trends in Research Tools Supporting Genome Editing

Applications”Scientific Customer Support, New England Biolabs, USA

Allen (Chia En) Lien M.D., DrPH“The Development of COVID-19 Vaccine-a case study”

Director, International and Governmental AffairsMedigen Vaccine Biologics Corp., Taiwan

Prof. Dr. Holger Puchta“Application of CRISPR/Cas to Plants: From Gene Editing to

Chromosome Engineering”Director of the Botanical Institute, Karlsruhe Institute of Technology,

Germany

Michael Ward„Dealing with COVID-19, Where are We Now?“

Global Head of Thought Leadership Sales, Clarivate, United Kingdom

Discussion“Society Future with Gene Editing”

Moderator: Monika Paulė, PhDParticipants:

1. Prof. Dr. Virginijus Šikšnys2. Dr. Karl von Laer

3. Prof. Dr. Holger Puchta

Kristina Daniūnaitė, PhD“Tracing Asymptomatic SARS-CoV-2 Carriers through Environmental

Surface Testing”Junior Research Fellow, Vilnius University Life Sciences Centre,

Lithuania

14:50-17:30

Startup Pitch Battle (Live)

Session 8: Early Drug Discovery and Clinical Development Powered by

Northway Biotech(14:15-16:05)

Prof. Vladas Algirdas BumelisTopic – TBC

CEO and Chairman of the Board, Northway Biotech, Lithuania

Prof. Ali Mobasheri,“Osteoarthritis: Phenotypes, Endotypes and Emerging Therapeutics”President, Osteoarthritis Research Society International (OARSI), USA

Karen Noonan“Bringing the Trial to the Patient – Decentralized Trials as the New

Normal”Senior Vice President of Global Regulatory Policy, Association of

Clinical Research Organizations, USA

Discussion:How to Accelerate Drug Development without any Compromise on

Data Integrity and Patient’s Safety??Moderator: Regina Auškalnienė, MD

Participants:1. Ali Mobasheri, 2. Karen Noonan,

3. Prof. Vladas Algirdas Bumelis4. Choon K. Oh, PhD

Participants of the Exhibition

Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world’s most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.comUnited Kingdom

Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company’s wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Lithuania

Novartis provides healthcare solutions that improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging healthcare issues. Lithuania

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Lithuania

Teva has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Lithuania

Carl Zeiss Microscopy is part of the Carl Zeiss group, a leading organization of companies operating worldwide in the optical and optoelectronical industry. ZEISS is one of the world leading manufacturers of microscopes. In addition to excellent light-/ion- and electron microscopes, ZEISS also manufactures a diverse range of fluorescence optical sectioning systems as well as high-resolution x-ray microscopes. Microscope systems by Carl Zeiss are much more than just hardware. A dedicated and well-trained sales force, an extensive support infrastructure and a responsive service team enable customers to use their ZEISS instruments to their full potential. Germany

CasZyme aims to develop new discoveries and top-quality research in the field of CRISPR based Molecular Tools by providing research services and exploring new Cas proteins for various industries and applications.Lithuania

Droplet Genomics aims to make the high-throughput exploration of biology accessible to more researchers. Company’s approach is integration of different technologies to deliver elegant solutions and novel tools for high-throughput research applications using droplet microfluidics workflows.Lithuania

Laborama top-notch solutions for scientific and laboratory research in the Baltic region. Quality solutions for Flow Cytometry, Cell Biology, Industrial and Clinical Microbiology, Molecular Biology and DNA based Genetic Research.Lithuania

Teltonika Telemedic designs and manufactures intelligent telemedicine devices, embracing global healthcare challenges with smart solutions. Combining the 23 years of experience in creating IoT devices and the knowledge from medical professionals, the company aims to deliver accessible solutions to various communities, healthcare professionals, the elderly and the most vulnerable people in society.Lithuania

Latvia MGI Tech (MGI Latvia) is a subsidiary of MGI Tech Co., Ltd. (MGI), a global leader in life science innovation, established in 2016 and now operating in more than 50 countries and regions serving more than 1000 customers worldwide. MGI is is committed to enabling effective and affordable healthcare solutions for all. Based on its proprietary technology, MGI produces sequencing devices, equipment, consumables and reagents to support life science research, medicine and healthcare.Latvia

MediTox s.r.o. is a GLP-certified preclinical contract research organization offering a wide range of preclinical development services taking advantage of wealth of experience in variety of therapeutics areas, biotechnology, chemical and agrochemical industry and research collaboration with universities and research institutions.Czech Republic

AAA-A2 Cargo is a freight forwarding group focused on design, development and execution of Time & Temperature sensitive logistics services across the Globe.Lithuania

Skrivanek translation agency belongs to the biggest international chain of translation agencies in Central and Eastern Europe. The company provides professional translation and interpretation services, arrangement of DTP and CAT tools, localization, transcription of texts, copywriting, language courses. Lithuania

Vorto Gama is providing solutions for Biotech, Pharmaceutical, Food&Beverage, Laboratory industries for nearly 25 years, by offering equipment, consumables and services of well-known manufacturers, such as Pall Biotech, Fortebio, AEB, Centec. Kern&Sohn , Boeco, Phenomenex.Lithuania

We are a company devoted to the introduction of innovative molecular diagnostics tests into medical practice. The company is focused on the development of non-invasive means for diagnostics. Proprietary technologies allow for sensitive detection and quantification of nucleic acid biomarkers in body fluids. This is a convenient, non-invasive method of diagnostics that enables physicians to precisely diagnose the disease and patients can avoid inconvenient and in some cases even harmful invasive procedures.Lithuania

MedPharm is the world’s leading contract provider of topical and transdermal formulation development, performance testing and manufacturing services. With Centers of Excellence in the USA and UK, MedPharm’s team are experts at reducing risk and accelerating development times for proprietary and generic pharmaceutical customers. Well-established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognized for their scientific rigor by regulators and investors. Pioneering research is fundamental to what we do here at MedPharm and with highly automated processes and proprietary technology, we’re changing the way our industry looks at topical formulation development. MedPharm has fully established Centres of Excellence in Durham, NC, USA and Guildford, Surrey, UK.USA

Mavis specializes in the supply of chemicals and customer service in nearly all fields of production. Mavis offers products for various industries. We are a loyal business partner ensuring top-quality service.Lithuania

Biotecha delivers, installs and maintains industrial and laboratory equipment and it is one of the few companies in the Baltic countries with many years of experience in life sciences, pharmaceutical, food and beverage technologies.Lithuania

Gruppo FOS Lithuania is the Italian daughter company working in R&D, Biomedical Engineering, Electronics, Technology Transfer areas. It cooperates with leading Italian and Lithuanian research institutions in joint laboratories and is a patent holder of “Method and biomedical electronic equipment thereof for monitoring human condition after stroke”.Lithuania

Recipharm is a leading contract development and manufacturing partner to the pharmaceutical and biopharmaceutical industries. A top 5 CDMO, we deliver quality services and products, at the right time for our customers and the global markets they serve. With significant operations in technically advanced pharmaceutical forms including sterile injectables and inhaled products we are able to support customers from early phase development through scale-up and into commercial manufacture. Our global footprint, comprising over 30 facilities worldwide, means our customers rely on us for support when it comes to accessing new markets.Sweden

CEBINA uniquely supports life science entrepreneurs and early-stage start-up companies and develops cutting-edge biotech projects.Austria

UQUIFA group provides support to originator and generic customers for chemical development & production of intermediates and API in both clinical trials and commercial phases. Spain

Semetron is active in the medical field – its main business fields are planning and selling, as well as the servicing and repair of hospital equipment, disposable items and other healthcare products.Estonia

Labema is a Finnish based Life Science and Biotechnology organization of experts, that imports, promotes and delivers first class diagnostic equipment and supplies to healthcare, food industry, and research laboratories. Labema was founded in 1988, and has offices in Finland, Estonia and Lithuania. Findalnd

GenScript Biotech Corporation is a leading life science research, application service, and product provider. It applies its proprietary technology to various fields, from basic life sciences research to translational biomedical development, industrial synthetic products, and cell therapeutic solutions.Netherlands

BLIRT, Biolab Innovative Research Technologies, is a European Biotech Company that started as a Technical University spin-off over 25 years ago to become a well-established recombinant enzyme manufacturer in the Life Science Industry. Poland

LGC Standards is a high-quality manufacturer and distributor of certified and analytical reference materials, pharmaceutical impurities, drug standards, biological standards and proficiency testing schemes for life sciences, food, industrial market sectors, etc.Poland

NOVA is a team of product, application and service specialists experienced in different fields of life sciences. We are local sales and service partner for instruments and consumables used in laboratories and industrial processes. Lithuania

World Courier for more than 50 years has provided unparalleled specialty logistics services to drive the commercial success of our partners around the globe, delivering peace of mind through world-class supply chain programs, transportation services, storage of time and temperature sensitive products. Lithuania

Pioneering the technologies for generative protein design at the intersection of synthetic biology and AI.Lithuania

dHealthIQ is a Digital Therapeutics (‘DTx’) company, enabling healthcare providers to treat and manage chronic cardiometabolic diseases based on evidence-based and personalised interventions directly to the patient. Combining professional medical expertise and AI technology, dHealthIQ therapies use medical, lifestyle, and behavioural data to assist in the continuous treatment process.Lithuania

IQVIA takes an analytics-infused approach to commercialization, helping life sciences companies take advantage of the latest tools, techniques, and deep healthcare expertise. The result - reinvigorated solutions focused on scalable resources, precision insights, and actionable ideas.Lithuania

We are a real estate project development, construction, and management company distinguished by modern architecture, technological progress and energy efficiency.Lithuania

Stemmatters is a Portuguese CDMO offering development and cGMP manufacturing services for cell and tissue-based therapies as well as blood-derived biologics. We are a vertically integrated company with resources and competences addressing all product development stages, from exploratory R&D to cGMP production. Our domain of expertise is Regenerative Medicine and we have the ability to work across a wide range of cells and product types. Portugal

Carlova Consult OÜ is a biotech distribution and counseling company from Tartu, Estonia, which has been representing several different scientific instrumentation and biotechnology companies in Estonia for over 20 years. Since 2008 we have been the official distributor of LI-COR Biosciences, which is the leading innovator in designing, manufacturing, and marketing instruments, measurement systems, and software for biological research. We are glad to announce that we are expanding our activity and we are now representing LI-COR Biosciences also in Latvia and Lithuania in addition to Estonia. LI-COR Biosciences Imaging instruments, reagents and analysis software are being used in more than 100 countries and in studies ranging from global climate change to cancer research.Estonia

Ardeola offers a wide range of various laboratory equipment for life science, analytical, clinical research and QC laboratories. Our partners ensure that we are always alongisde with the newest research technologies.Lithuania

Asahi Kasei Bioprocess is the global market leader in virus filtration, with its Planova™ virus removal filters having an unrivalled 30-year history of trusted use in the production of biotherapeutics. We aim to provide “Assurance Beyond Expectation” to pharmaceutical companies in the form of innovative yet exceptionally reliable bioprocess consumables, equipment and support services, to help them safely and efficiently produce medicines that patients can trust.Belgium

National pavilions participating in the virtual exhibition

ITALYITA – Italian Trade Agency is the Governmental agency that supports the business development of Italian companies abroad and promotes the attraction of foreign investment in Italy.

AdvancedParticlesTechnologySolutions

Belgian pavilion is presented by Walonia.be.The Wallonia Export-Investment Agency or AWEX, is the public service in Wallonia in charge both of attracting foreign investment to Wallonia-Belgium and to stimulate foreign trade by assisting the companies established in our region in their export endeavours.

BELGIUM

South Korean pavilion is presented by KIC Europe.In 2014, Korea Innovation Center (KIC) Europe has been established to build up networks in research and innovation between Korea and the EU. To accelerate the activity of growing innovation; helping startups, business matching, and technology commercialization, they moved to Berlin on 16, Mar 2017.

SOUTH KOREA

Austrian pavilion is presented by Advantage Austria.Advantage Austria is the trade promotion rganisation of the Austrian Federal Economic Chamber.

AUSTRIA

UK pavilion is presented by Innovate UK EDGE at UCL.Innovate and expand into new markets with help from the Innovate UK EDGE team at UCL. If you’re an innovation-led small to medium sized business, startup or spinout, our specialists can support you along your growth journey to scale. As an integral part of Innovate UK we collaborate with R&D intensive businesses to drive economic growth. Through a bespoke approach we can help you build innovation into your business; source funding to scale; take your product or service into new markets; access knowledge exchange opportunities.

Canadian pavilion is presented by Office of the Canadian Embassy, Lithuania – your partner in doing business with Canada. Facilitation of partnering an investment; promotion of Canada’s economic interests in Lithuania.

UKCANADA

Baltic research institutes, universities and other participants

Poster session1. Michela CapraniUsing An Ensemble To Identify And Classify Macroalgae Antimicrobial peptides

2. Mindaugas IlickasMonitoring of pulse arrival time (PAT) by using electrocardiogram (ECG) and photoplethysmogram (PPG) signals

3. Žana KapustinaHigh-precision characterization of microbial communities by the analysis of 16S rRNA gene genomic context

4. Milda Vanagaitė-ŽičkienėThe role of peritoneal phagocytes in the concomitant tumor immunity elicited by primary SL2 lymphoma

5. Ugnė DrazdauskienėSemi-targeted sequencing of fusion transcripts in prostate cancer

6. Lukas ŠimkusLiposomal Doxorubicin exhibits reduced uptake in T-lymphoma cells following short term exposure in vitro

7. Marius ButkevičiusAPPLICATION OF MARCUS THEORY TO ANALYSIS OF HORSERADISH PEROXIDASE COMPOUND II-CATALYSED OXIDATION REACTION

8. Ausra UnguryteExpression of retinoic acid producing enzymes strongly correlates with expression of main chondrogenic markers in cultured chondrocytes

9. Rosita MakauskienėMultimodal System for Personalized Post-Stroke Rehabilitation

10. Greta VarkalaiteMicroRNA signatures in atrophic gastritis and gastric cancer

11. Rūta InčiūraitėColonic tissue and epithelial cell microRNA composition in active and quiescent Ulcerative Colitis

12. Justina MedžiūnėIntroduction of universal priming sites to nucleic acids via oligonucleotide-tethered 2’,3’-dideoxynucleotide terminators

13. Gabija DičpetrytėInfluence of Gallic Acid on [PSI] Prion Formation in Yeast Cells

14. Laura SakalauskieneREAGENTLESS GLUCOSE BIOSENSOR BASED ON 1,10-PHENANTHROLINE-5,6-DIONE MODIFIED GOLD NANOSTRUCTURES

15. Eglė OvsianaitėT7 RNA Polymerase Mutants with Altered Substrate Specificity

16. Rokas LukoseviciusTranscriptome analysis revealed putative target genes of CRC associated miR1246 and its isoforms

17. Vytenis PetkeviciusAssociations of long non-coding RNA HOTAIR expression with gastric cancer and preneoplastic conditions

18. Darja NikitinaAnalysis of blood microbiome in patients with gastric cancer

19. Edvinas SkliutasBio-derived 3D printable resin for medical parts

20. Airidas RudžianskasCreation of a Sup35 Protein Δ243–249 Variant and Analysis of its Synthesis in Saccharomyces cerevisiae Cells

21. Raminta VaičiulevičiūtėDifferences in Electrostimulation-Dependent Cellular Responses in Human Mesenchymal Stem Cells and Chondrocytes

22. Ilona UzielieneHuman Mesenchymal Stem Cell Chondrogenic Differentiation Using Cell Sheet Technology

23. Sarah MarkhamIn Silico Design of Needle Surfaces for Improved Contrast in Endoscopic Ultrasound Imaging

24. Augustas PivoriunasExosomica - developer of innovative therapy against Parkinson‘s disease

25. Justas ŠidiškisRegulation of hypoxia-induced alternative Tau splicing

26. Jurga JeršovaitėBIOCOMPATIBILITY EVALUATION OF OPTICALLY 3D PRINTED SCAFFOLDS AND THEIR IMPROVEMENT

27. Mindaugas JuozapaitisThe development of the class 2 CRISPR-Cas based cellular system for studying the genome packaging of influenza viruses

28. Monika Kunigonyte, Karolina Lubyte, Ieva Kubiliute, Birute Zablockiene, Ligita JancorieneRisk factors and outcomes of hospitalized COVID-19 patients in Vilnius University Hospital Santaros Klinikos during the first pandemic wave

29. Benediktas KurlinkusCEACAM6’s Role as a Chemoresistance and Prognostic Biomarker for Pancreatic Cancer: A Comparison of CEACAM6’s Diagnostic and Prognostic Capabilities with Those of CA19-9 and CEA

30. Skaiste ArbaciauskaiteUtilization of the direct LAMP method for SARS-CoV-2 detection and for the determination of patient infectivity from clinical gargle water samples

31. Andrejus CernovasPatient engagement instruments for the improvement of healthcare quality in Lithuania

32. Gedmante RadziuvieneIntratumoral heterogeneity and immune response indicators to predict overall survival in HER2-bordeline (IHC2+) breast cancer patients

33. Samanta Grubyte, Ligita Jancoriene; Jurgita Urboniene Case-control study of hepatitis C virus (HCV) infection risks factors at the Vilnius University Hospital Santaros Klinikos: toward a simple risk assessment tool for HCV infection

34. Ignas Klėjus, Rūta Mameniškienė, Lauryna Pranė, Paulė Stulginskaitė,

Viktoras Sutkus, Antanas Kiziela, Rimantė Čerkauskienė, Augustina Jankauskienė Personalized care for Rare Diseases based on innovation and international European cooperation at Vilnius University Hospital Santaros Klinikos

35. Dovilė Ramanauskaitė, Roma Puronaitė, Greta Burneikaitė, Justas Trinkūnas, Monika Grigentytė, Rimgaudas Katkus, Laimis Dambrauskas, Audronė Jakaitienė, Edita Kazėnaitė Assessing severity of adverse drug reactions using machine learning approach

36. Roma Puronaitė, Kristina Švaikevičienė, Greta Burneikaitė, Dovilė Ramanauskaitė, Justas Trinkūnas, Vytautas Kasiulevičius, Edita KazėnaitėIdentification of Anxiety and Depression Patterns in Multimorbid Patients: A Case of Secondary Use of Administrative Health Data

37. Daniel NaumovasThe Importance of Biobanks in the Presence of a Pandemic

38. Ramunė Žilinskaitė – Tamašauskė, Povilas Barasa, Emilija Baltrukonyte, Natalija Krestnikova, Gilvydas Verkauskas, Daiva Baltriukienė, Aivaras Grybas, Milda Alksne, Ieva Rinkunaite, Darius Dasevicius, Arunas Zelvys, Virginija Bukelskiene

IN VITRO INVESTIGATON OF GENE EXPRESSION MARKERS IN FIBROTIC URETHRAL AND URETERAL TISSUE CELLS

39. Tautvilė SmalinskaitėDYNAMICS OF SARS-CoV-2 NASOPHARYNGEAL RT-PCR ASSAYS IN COVID-19 PATIENTS

40. Ursule KalvaityteInterleukin 1β-Induced Biomarker Changes in Human Articular Cartilage Explant Model

41. Kristina Žukauskaitė, Aistė Gerulaitytė, Augustinas Matulevičius, Mantas Trakymas, Albertas Ulys, Rasa Sabaliauskaitė, Sonata Jarmalaitė ANALYSIS OF DNA METHYLATION BIOMARKERS IN MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING AND ULTRASOUND-GUIDED PROSTATE BIOPSIES

42. Maija DambrovaPreclinical Testing Services and Platform for Drug Discovery and Development of New Therapeutic Modalities

43. Goda StriogaiteDETECTION OF 18S RIBOSOMAL DNA FRAGMENT IN CEREBROSPINAL FLUID FOR THE DIAGNOSIS OF INVASIVE CNS FUNGAL INFECTION

44. Muhammad HamzahEstablishing a Rex1 reporter based CRISPR/Cas9 screening system to facilitate mechanistic analysis of full pluripotency acquisition using paused iPSCs

45. Andrius RapalisPain Recognition from Finger Plethysmography using Neural Networks

46. Mantas JucevičiusMagnetic Sensor for Intra-Oral Continuous Jaw Motion Tracking

47. Raimonda KubiliūtėNovel urinary DNA methylation biomarkers for kidney cancer detection and prognosis

48. Justinas ŠlikasRapid SARS-CoV-2 viral sequencing library preparation for Illumina™ platforms

49. Justas ŠidiškisThe Impact of PTBP1 on Alternative Splicing of MAPT Pre-mRNA Under Normoxic and Hypoxic Conditions

50. Eva MoreinoA New Skin Product For Metabolic Syndrome Patients

VIOLET.vision next level disinfection standard and management applying UV-C light. Our solution saves time and cost.

Company MB DentFuture is developing product to help dentists from to diagnose risk to have osteoporosis.

Labzero is manufacturing machinery enabling the reuse of plastic waste for life science companies aiming to be net zero.

Revolab is developing remote blood testing platform for health oriented consumer to track and improve health.

BALTYMAS combines scientific experience and knowledge with enterprise for generation of novel biotechnology products.

Startup company RamaZottius Lab created a prototype of medical device in the treatment of Periodontitis.

Cumulatis participates in development services and custom technology transfer activities.

Lipidohms company is developing phospholipid bio sensor for pathogen detection from human saliva.

BrachyDOSE is a game changing technology made to improve cancer treatment in radiotherapy for most common cancer cases.

AIDOT is medical ICT company that develops AI-based cervical cancer remote screening system.

The company develops innovative products in the field of life sciences using only natural materials.

Global medical device company with the world’s fastest sterilizer and biological regenerative and active surface treatment.

TouchCare increases physical and mental wellbeing within domiciliary care using AI and patented touch-communication.

Mediaiplus provides customized clinical trials protocols for clients who need curated clinical trials data.

Integral Solutions is developing next generation probiotics for mental health, which is a revolution in psychiatry.

NLSQL is SaaS to empower employees with chat interface to poorly accessible corporate data to inform and speed decisions.

Non-invasive Vagus nerve stimulator to decrease stress, anxiety and insomnia.

FemiBox is a complex set of elements for gynecologists and pregnant women, to improve remote gynecological medicine.

Startups participating at Life Sciences Baltics 2021

NP5, ltd innovative product: “Smart relaxation system – „Chair“ with Artificial intelligence for children with Autism”.

BioMinds is developing an innovative approach for neurological rehabilitation.

Extratique is creating a one of a kind synergistic phyto-cannabinoid prebiotic nutraceutical tailored for gut health.

xT enables engineers and scientist to develop and optimize machine parameters and chemical compositions 10x faster.

Tausan robotics - company developing robotic assistant for people with limited mobility and need for constant care.

Aichom - #1 Caregiver’s library for families of people living with dementia & smartwatch integration for peace of mind.

Exosomica is developing an innovatives therapies to help people suffering from Parkinson`s decease.

Net-Health is a MedTech company helping people with chronic conditions manage their condition through home monitoring.

MUVi kills superbugs & decontaminates surfaces/air in healthcare and workplaces. Our IP is IoT Data ML platform.

facilitates healthcare delivery regardless of IT infrastructure barriers with accessible offline apps.

Startup masterclasses programme

Life Sciences Baltics Sponsors

Life Sciences Baltics Partners

• No coding required• Works with partial annotations• No need for local resources, works in the cloud• Multidimensional web viewer with annotation tools for ML• Report generation with object measurements• Free for academia

To signup for your free account visit: www.apeer.com

APEER ML

Be smart and annotate only the regions that add information to the training model.

A comprehensive NIPTfor 23 pair chromosomes

TEST TODAY FOR A PEACEFUL P R E G N A N C Y

www.trisomytest.com

MXG_08906_TTC_INZERCIA_EN_210x297.indd 1 06/09/2021 11:10

“Teva is committed to improving the lives of patients by delivering quality medicines. In the Baltics, Teva operates with both commercial and production site under one legal entity and we are proud not only for being the biggest provider of, but also for manufacturing and exporting products to over 50 countries, including EU, USA and Japan.”

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. Teva is a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world in 60 markets take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. We are a leader in the field of generic medicines, and we also add to our portfolio of medicines with a variety of specialized innovative and biological medicines.Learn more at www.teva.lt.

– Agita Birnbauma, General Manager Teva Baltics.

200million people

3,50

0

products

6 markets

NPS-LT-00008

Roche was one of the first companies to bring targeted treatments to patients. With our combined strengths in pharmaceuticals and diagnostics, we are driving personalised healthcare.

This year Roche is celebrating its 125-year anniversary. We are taking this as an opportunity to celebrate our history and the enduring purpose that guides us towards a sustainable and healthy future.

Roche is spearheading the next generation of healthcare. We are bringing together a unique understanding of human biology with new ways to analyse health data. Our vision is to ensure that the screening, diagnosis, treatment and even prevention of diseases will more quickly and effectively transform the lives of people - ensuring the right treatment for the right patient at the right time.

The science of medicine has allowed us to make incredible advances in diagnosing and treating diseases. Every person is unique, so are diseases. The digital revolution in healthcare provides new ways to collect high-quality data from each patient. This enables us to arrive at a deeper understanding of how to treat an individual. Only then can we see what distinguishes each of us as individuals, and translate that into personalised and thus improved care for every person.